Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MGNX -- MacroGenics -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (182)	6/11/2020 6:55:13 PM
From: scaram(o)uche	Respond to of 188

>> I personally believe that marg would beat trastuzumab by wide margin in naive patients << clinicaltrials.gov Exclusion......... "Any prior treatment for the current breast cancer" Seems that there are at least two believers, Dr. Krop and me. Yes!!!!!!!!!!

To: scaram(o)uche who wrote (182)	9/7/2021 6:52:07 PM
From: scaram(o)uche	Respond to of 188

Final analysis of the trial shows no significant benefit over T. ir.macrogenics.com But, re. CD16A.......... "A pre-specified, non-alpha-allocated exploratory analysis evaluated the effect of CD16A allelic variation on MARGENZA activity. Among the patients in the trial carrying a CD16A 158F allele, representing approximately 82% of study patients (437 of 536 patients), the median OS was prolonged by 2.5 months in the MARGENZA arm compared to the trastuzumab arm (23.3 months versus 20.8 months; HR=0.86; 95% CI: 0.69-1.08; nominal P=0.19). The numerical OS advantage was observed in the subgroup of CD16A patients who were homozygous for the F-allele at position 158 (i.e., “F/F” patients) in favor of MARGENZA plus chemotherapy (HR=0.72; 95% CI: 0.52-1.00; nominal P=0.05). In this subgroup, the median OS was 23.6 months in patients treated with MARGENZA plus chemotherapy (102 of 266 patients) compared to 19.2 months in patients treated with trastuzumab plus chemotherapy (90 of 270 patients)."